Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Diabetes and Endocrinology|January 30, 2019
Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reportsMeng H Tan, Ravi Iyengar, Kara Mizokami-Stout, et al.
Genetic Epidemiology|February 23, 2023
Evaluation of polygenic risk scores to differentiate between type 1 and type 2 diabetesMuhammad Shoaib, Qiang Ye, Heidi IglayReger, et al.
Diabetes Care|June 28, 2007
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemiaMark A Deeg, John B Buse, Ronald B Goldberg, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesImre Pavo, György Jermendy, Tamas T Varkonyi, et al.
Clinical Therapeutics|December 26, 2007
Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparisonDavid C Robbins, Paul J Beisswenger, Antonio Ceriello, et al.
Clinical Therapeutics|June 18, 2003
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitusMatthias Herz, Don Johns, Jesus Reviriego, et al.
Journal of Diabetes Science and Technology|March 1, 2018
Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery SystemDarlene M Dreon, Trevor M Hannon, Brett Cross, et al.
Diabetes Care|June 29, 2005
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaRonald B Goldberg, David M Kendall, Mark A Deeg, et al.
Circulation|February 12, 2024
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)Jennifer B Green, Brendan M Everett, Alokananda Ghosh, et al.
JAMA Internal Medicine|May 22, 2023
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical TrialDeborah J Wexler, Ian H de Boer, Alokananda Ghosh, et al.
Pageof 4